AK112 for advanced clear cell kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called AK112 (Yiwoxidan Anti) in people with advanced clear cell kidney cancer who cannot take TKI medications. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your kidney cancer must be the clear cell type and have spread to other parts of the body.
- You must not have received any previous drug treatment for advanced kidney cancer.
- You must be able to get around (ECOG score of 0 or 1).
- You cannot have had immunotherapy or targeted therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study tests a combination of two drugs (toripalimab and axitinib) as the first treatment for advanced kidney cancer that has clear cell features. The goal is to see if this drug combo can shrink tumors and possibly allow some patients to avoid or delay surgery to remove the kidney. Participation requires a tumor biopsy that shows a specific immune pattern.
This trial tests a new immunotherapy drug, AK112, for people with a specific type of lung cancer (non-squamous) that has certain genetic changes and has stopped responding to targeted therapy. The goal is to see if AK112 can help when targeted treatments no longer work.
This study tests a new drug called AK112 for people with advanced or metastatic clear cell kidney cancer who have not had any prior treatment. The goal is to see if AK112 can shrink tumors or slow cancer growth.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.